Metabolic adverse effects of antipsychotics: the state of the problem and management options
https://doi.org/10.14341/omet12935
Abstract
Antipsychotic drugs are widely used for many psychiatric disorders, such as schizophrenia, bipolar affective disorder, delusions and hallucinations due to neurological disorders, depression with severe psychotic symptoms. Metabolic disorders including weight gain, dyslipidemia and hyperglycemia are one of the most common side effects of antipsychotic therapy. Psychiatric patients have higher risk of cardiovascular disease, so that the development of metabolic side effects is an important clinical problem that should be solved. Antipsychotic-induced weight gain may cause distress that leads to antipsychotics withdraw and repeated hospitalizations.
Lifestyle changes, correction of the antipsychotic treatment, additional medications and their combination are the possible solutions of antipsychotic metabolic side effects. Lifestyle modification is a first-line therapy that should complement other options, when it feasible. At the same time, it can be extremely difficult for patients receiving antipsychotic to adhere dietary and physical activity recommendations. Replacing an antipsychotic with a milder drug is not always possible and may not be enough effective. Metformin seems to be the most well-studied, safe and effective agent that is prescribed to deal with antipsychotic-induced weight gain and associated metabolic disorders. Glucagon-like peptide type 1 receptor agonists and thiazolidinediones are mentioned as alternative medications, but clinical data on their efficacy and safety in this patient group are extremely limited. Dyslipidemia can develop as an independent antipsychotic side effect even without an increase in body weight. The most effective treatment, as in the general population, is statin therapy. However, the joint appointment of statins and antipsychotic significantly increases the risk of adverse reactions, such as myalgia, myopathy, increased creatine kinase levels, due to the competition of drugs for the cytochrome system.
It is still unknown what scales should be used for cardiovascular risk stratification in patients taking antipsychotic and whether it is possible to use metformin to prevent antipsychotic-induced weight gain, and if so, how to select patients for whom such therapy can be indicated. Finally, more clinical trials are needed to evaluate the efficacy and safety of other classes of hypoglycemic and lipid-lowering drugs in patients on antipsychotics.
About the Authors
A. V. BalashovaRussian Federation
Anastasiya V. Balashova.
16 1-st Leonova Str, 129226 Moscow
Researcher ID: GXV-9550-2022
Competing Interests:
None
D. V. Mamleeva
Russian Federation
Diana V. Mamleeva.
Moscow
Competing Interests:
None
L. V. Machekhina
Russian Federation
Liubov V. Machekhina - MD, PhD.
Moscow
Competing Interests:
None
E. N. Dudinskaya
Russian Federation
Ekaterina N. Dudinskaya, MD, PhD.
Moscow
Scopus Author ID: 55308206900; Researcher ID: H-3281-2013
Competing Interests:
None
References
1. Boyd-Kimball D, Gonczy K, Lewis B, et al. Classics in chemical neuroscience: chlorpromazine. ACS Chem Neurosci. 2019;10(1):79-88. doi: https://doi.org/10.1021/acschemneuro.8b00258
2. Evsegneev R. Metabolic side effects of antipsychotic therapy. Psychiatry, psychotherapy and clinical psychology. 2020;11(1):146-154. (In Russ.). doi: https://doi.org/10.34883/PI.2020.11.1.014
3. Holt RIG. Association between antipsychotic medication use and diabetes. Curr Diab Rep. 2019;19(10):96. doi: https://doi.org/10.1007/s11892-019-1220-8
4. Lieberman JA, First MB. Psychotic disorders. N Engl J Med. 2018;379(3):270-280. doi: https://doi.org/10.1056/NEJMra1801490.
5. Roessner V, Eichele H, Stern JS, et al. European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment. Eur Child Adolesc Psychiatry. 2022;31(3):425-441. doi: https://doi.org/10.1007/s00787-021-01899-z
6. Vazquez GH, Bahji A, Undurraga J, et al. Efficacy and tolerability of combination treatments for major depression: antidepressants plus second-generation antipsychotics vs. esketamine vs. lithium. J Psychopharmacol. 2021;35(8):890-900. doi: https://doi.org/10.1177/02698811211013579
7. Kruizinga J, Liemburg E, Burger H, et al. Pharmacological treatment for psychotic depression. Cochrane Database Syst Rev. 2021;12(12):CD004044. doi: https://doi.org/10.1002/14651858.CD004044.pub5
8. Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018;17(3):341-356. doi: https://doi.org/10.1002/wps.20567
9. Grinchii D, Dremencov E. Mechanism of action of atypical antipsychotic drugs in mood disorders. Int J Mol Sci. 2020;21(24):9532. doi: https://doi.org/10.3390/ijms21249532
10. Danilov DS. 60 let antipsikhoticheskim sredstvam (k voprosu ob ikh klassifikatsii). Nevrologiya, neiropsikhiatriya, psikhosomatika. 2012;(4):24-33. (In Russ.).
11. Drobizhev MY, Ovchinnikov AA. Zachem nuzhna sovremennaya klassifikatsiya antipsikhotikov? Russkii meditsinskii zhurnal. 2012;(29):1449. (In Russ.).
12. Oleichik IV, Shishkovskaya TI, Baranov PA, Nikiforova IY. Features of clinical use of brexpiprazole, the new atypical antipsychotic of the third generation: experience and perspectives. Psikhiatriya. 2022;20(3):134-142. (In Russ.). doi: https://doi.org/10.30629/2618-6667-2022-20-3-134-142.
13. Petrova NN, Sofronov AG. Antipsychotics: from first to third generation. Pharmacy formulas. 2020;2(4):82-89. (In Russ.). doi: https://doi.org/10.17816/phf55260
14. Rossiiskoe obshchestvo psikhiatrov. Klinicheskie rekomendatsii po vedeniyu i lecheniyu patsientov s shizofreniei (vzroslye). 2021. (In Russ).
15. Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939-951. doi: https://doi.org/10.1016/S0140-6736(19)31135-3
16. Kritharides L, Chow V, Lambert TJ. Cardiovascular disease in patients with schizophrenia. Med J Aust. 2017;206(2):91-95. doi: https://doi.org/10.5694/mja16.00650
17. Raben AT, Marshe VS, Chintoh A, et al. The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment. Front Neurosci. 2018;11(2):114-126. doi: https://doi.org/10.3389/fnins.2017.00741
18. De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8(2):114-126. doi: https://doi.org/10.1038/nrendo.2011.156
19. Mitchell AJ, Vancampfort D, Sweers K, et al. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis. Schizophr Bull. 2013;39(2):306-318. doi: https://doi.org/10.1093/schbul/sbr148
20. Yunilaynen OA, Oleichik IV, Sizov SV, et al. Efficacy of metformin for treatment and prevention of antipsychotic-induced overweight and obesity in women: an open-label, randomized, prospective placebo-controlled study. Obesity and metabolism. 2021;18(2):198-209. (In Russ.). doi: https://doi.org/10.14341/omet12684.
21. Barton BB, Segger F, Fischer K, et al. Update on weightgain caused by antipsychotics: a systematic review and meta-analysis. Expert Opin Drug Saf. 2020;19(3):295-314. doi: https://doi.org/10.1080/14740338.2020.1713091
22. Cooper SJ, Reynolds GP, Barnes T, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol. 2016;30(8):717-748. doi: https://doi.org/10.1177/0269881116645254
23. Kibitov AO, Mazo GE. Metabolic side effects of atypical antipsychotics: individual variability and genetic risk. Social and clinical psychiatry. 2018;28(1):90-100. (In Russ.).
24. Nasyrova RF, Tolmachev MY, Sychev DA, et al. Mechanisms of development of antipsychotic-induced metabolic disorders: pharmacogenetic aspect. Bulletin of Siberian Medicine. 2017;16(4):30-41. (In Russ.) doi: https://doi.org/10.20538/1682-0363-2017-4-30-41
25. Singh R, Bansal Y, Medhi B, Kuhad A. Antipsychotics-induced metabolic alterations: Recounting the mechanistic insights, therapeutic targets and pharmacological alternatives. Eur J Pharmacol. 2019;(844):231-240. doi: https://doi.org/10.1016/j.ejphar.2018.12.003
26. DeHert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10(1):52-77. doi: https://doi.org/10.1002/j.2051-5545.2011.tb00014.x
27. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res. 2004;70(1):1-17. doi: https://doi.org/10.1016/j.schres.2004.01.014
28. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second-generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2-3):225-233. doi: https://doi.org/10.1016/j.schres.2010.07.012
29. Vancampfort D, Correll CU, Galling B, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry. 2016;15(2):166-174. doi: https://doi.org/10.1002/wps.20309
30. Mamakou V, Thanopoulou A, Gonidakis F, et al. Schizophrenia and type 2 diabetes mellitus. Psychiatriki. 2018;29(1):64-73. doi: https://doi.org/10.22365/jpsych.2018.291.64
31. Liao CH, Chang CS, Wei WC, et al. Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: a population-based study. Schizophr Res. 2011;126(1-3):110-6. doi: https://doi.org/10.1016/j.schres.2010.12.007
32. Bushe C, Shaw M, Peveler RC. A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol. 2008;22(S2):46-55. doi: https://doi.org/10.1177/0269881107088435
33. Yunilainen OA, Starostina EG, Dzeranova LK, et al. Epidemiology, diagnostics and treatment of antipsychotic-induced hyperprolactinemia. Russkii meditsinskii zhurnal. 2017;(1):30-36. (In Russ.).
34. Maguire GA. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry. 2002;63(S4):56-62.
35. Yunilaynen OA, Dorovskikh IV. Antipsychotic-induced hyperprolactinemia. Social and clinical psychiatric. 2013;23(1):100-104. (In Russ.).
36. Gorobets LN, Mazo GE. Neuroleptic hyperprolactinemia medicamentous correction. V.M.Bekhterev review of psychiatry and medical psychology. 2017;(2):79-85. (In Russ.).
37. Posawetz AS, Trummer C, Pandis M, et al. Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study. BMC Endocr Disord. 2021;21(1):81. doi: https://doi.org/10.1186/s12902-021-00733-6
38. Dzeranova LK, Mokrysheva NG, Barmina II, Ginijatullina EN. Metabolicheskie jeffekty prolaktina. Vestnik reproduktivnogo zdorov'ja. 2008;(3-4):29-33. (In Russ.).
39. Lopez-Vicchi F, De Winne C, Ornstein AM, et al. Severe hyperprolactinemia promotes brown adipose tissue whitening and aggravates high fat diet induced metabolic imbalance. Front Endocrinol (Lausanne). 2022;(13):25-34. doi: https://doi.org/10.3389/fendo.2022.883092
40. Montejo AL, Arango C, Bernardo M, et al. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. Front Neuroendocrinol. 2017;(45):25-34. doi: https://doi.org/10.1016/j.yfrne.2017.02.003
41. Green CA, Yarborough BJ, Leo MC, et al. The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial. Am J Psychiatry. 2015;172(1):71-81. doi: https://doi.org/10.1176/appi.ajp.2014.14020173
42. Daumit GL, Dickerson FB, Wang N-Y, et al. A Behavioral Weight-Loss Intervention in Persons with Serious Mental Illness. N Engl J Med. 2013;368(17):1594-1602. doi: https://doi.org/10.1056/NEJMoa1214530
43. Daumit GL, Dickerson FB, Wang N-Y, et al. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Obes Res. 2004;12(2):362-368. doi: https://doi.org/10.1038/oby.2004.46
44. Kanagasundaram P, Lee J, Prasad F, et al. Pharmacological interventions to treat antipsychotic-induced dyslipidemia in schizophrenia patients: asystematic review and meta-analysis. Front Psychiatry. 2021;(12):642403. doi: https://doi.org/10.3389/fpsyt.2021.642403
45. Correll CU, Howes OD. Treatment-Resistant Schizophrenia. J Clin Psychiatry. 2021;82(5):352-358. doi: https://doi.org/10.4088/JCP.MY20096AH1C
46. Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of specialized diabetes care. Diabetes Mellitus. 2021;24(S1):1-235 (In Russ.). doi: https://doi.org/10.14341/DM12802
47. Wu R-R, Zhao J-P, Guo X-F, et al. Metformin Addition Attenuates Olanzapine-Induced Weight Gain in Drug-Naive First-Episode Schizophrenia Patients: A Double-Blind, Placebo-Controlled Study. Am J Psychiatry. 2008;165(3):352-358. doi: https://doi.org/10.1176/appi.ajp.2007.07010079
48. Jarskog LF, Hamer RM, Catellier DJ, et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry. 2013;170(9):1032-1040. doi: https://doi.org/10.1176/appi.ajp.2013.12010127
49. Fitzgerald I, O'Connell J, Keating D, et al. Metformin in the management of antipsychotic-induced weight gain in adults with psychosis: development of the first evidence-based guideline using GRADE methodology. Evid Based Ment Health. 2022;25(1):15-22. doi: https://doi.org/10.1136/ebmental-2021-300291
50. Jiang WL, Cai DB, Yin F, et al. Adjunctive metformin for antipsychotic-induced dyslipidemia: a meta-analysis of randomized, doubleblind, placebo-controlled trials. Transl Psychiatry. 2020;10(1):117. doi: https://doi.org/10.1038/s41398-020-0785-y
51. Boyda HN, Procyshyn RM, Tse L, et al. Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. J Psychiatry Neurosci. 2012;37(6):407-415. doi: https://doi.org/10.1503/jpn.110140
52. Smith RC, Jin H, Li C, et al. Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study. Schizophr Res. 2013;143(1):18-24. doi: https://doi.org/10.1016/j.schres.2012.10.023
53. Dedov II, Mokrysheva NG, Mel'nichenko GA, et al. Obesity. Clinical guidelines. Consilium Medicum. 2021;23(4):311-325. (In Russ.). doi: https://doi.org/10.26442/20751753.2021.4.200832
54. Ishøy PL, Knop FK, Broberg BV, et al. Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist—protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol. BMJ Open. 2014;4(1):e004158. doi: https://doi.org/10.1136/bmjopen-2013-004158
55. Siskind D, Hahn M, Correll CU, et al. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis. Diabetes Obes Metab. 2019;21(2):293-302. doi: https://doi.org/10.1111/dom.13522
56. Gonçalves P, Araújo JR, Martel F. Antipsychotics-induced metabolic alterations: focus on adipose tissue and molecular mechanisms. Eur Neuropsychopharmacol. 2015;25(1):1-16. doi: https://doi.org/10.1016/j.euroneuro.2014.11.008
57. Siwek M, Woron J, Gorostowicz A, Wordliczek J. Adverse effects of interactions between antipsychotics and medications used in the treatment of cardiovascular disorders. Pharmacol Rep. 2020;72(2):350-359. doi: https://doi.org/10.1007/s43440-020-00058-6
58. Webber MA, Mahmud W, Lightfoot JD, Shekhar A. Rhabdomyolysis and compartment syndrome with coadministration of risperidone and simvastatin. J Psychopharmacol. 2004;18(3):432-434. doi: https://doi.org/10.1177/026988110401800316
59. Laffin LJ, Bruemmer D, Garcia M, et al. Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers. J Am Coll Cardiol. 2023;81(1):1-12. doi: https://doi.org/10.1016/j.jacc.2022.10.013
60. Rossiiskaya assotsiatsiya ehndokrinologov. Klinicheskie rekomendatsii. Giperprolaktinemiya. 2016. (In Russ.).
61. Rusgis MM, Alabbasi AY, Nelson LA. Guidance on the treatment of antipsychotic-induced hyperprolactinemia when switching the antipsychotic is not an option. Am J Health Syst Pharm. 2021;78(10):862-871. doi: https://doi.org/10.1093/ajhp/zxab065
62. Hasan A, Falkai P, Wobrock T, et al; WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia — a short version for primary care. Int J Psychiatry Clin Pract. 2017;21(2):82-90. doi: https://doi.org/10.1080/13651501.2017.1291839
63. Pringsheim T, Kelly M, Urness D, et al. Physical health and drug safety in individuals with schizophrenia. Can J Psychiatry. 2017;62(9):673-683. doi: https://doi.org/10.1177/0706743717719898
Supplementary files
|
1. Figure 1. Mechanisms of antipsychotics metabolic side effects. | |
Subject | ||
Type | Исследовательские инструменты | |
View
(347KB)
|
Indexing metadata ▾ |
|
2. Figure 2. Approaches to antipsychotics metabolic side effects correction Disorders Developed on the Background of Antipsychotic Therapy. | |
Subject | ||
Type | Other | |
View
(350KB)
|
Indexing metadata ▾ |
Review
For citations:
Balashova A.V., Mamleeva D.V., Machekhina L.V., Dudinskaya E.N. Metabolic adverse effects of antipsychotics: the state of the problem and management options. Obesity and metabolism. 2022;19(4):431-441. (In Russ.) https://doi.org/10.14341/omet12935

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).